Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance

Abstract

HCC surveillance rates in commercially insured at-risk patients remain poor despite formalized guidelines, highlighting the need to develop interventions to improve surveillance rates.